drugset / Trial / NCT03847428
Assess Efficacy and Safety of Durvalumab Alone or Combined With Bevacizumab in High Risk of Recurrence HCC Patients After Curative Treatment
RandomizedParallel-groupQuadruple-blindTreatment
Summary
A global study to assess the efficacy and safety of durvalumab in combination with bevacizumab or durvalumab alone in patients with hepatocellular carcinoma who are at high risk of recurrence.
Timeline
- Start
- 2019-04-29
- Primary completion
- 2026-05-29
- Completion
- 2027-05-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | 15 mg/kg | Intravenous |
| Subject | Durvalumab | Monoclonal antibody | 1120 mg | Intravenous |